Research graph
References from Using Polygenic Risk Scores to Refine Risk and Outcomes in High-grade Serous Ovarian Cancer in Australia. Local targets link to admitted publications; unresolved targets remain external evidence.
Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership
10.1016/j.ygyno.2012.06.033 · 2012 · External reference
Prognostic factors and clinic-pathologic characteristics of ovarian tumor with different histologic subtypes-a SEER database population study of 41,376 cases
10.21037/tcr-23-58 · 2023 · External reference
Ovarian cancer statistics in Australia
External reference
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies
10.1371/journal.pmed.0050232 · 2008 · External reference
Unresolved reference
2020 · External reference
High grade serous ovarian carcinomas originate in the fallopian tube
10.1038/s41467-017-00962-1 · 2017 · External reference
Disparities in ovarian cancer survival in the United States (2001-2009): findings from the CONCORD-2 study
10.1002/cncr.31027 · 2017 · External reference
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
10.1016/s0140-6736(21)00731-5 · 2021 · External reference
Genetic/familial high-risk assessment: breast and ovarian
10.6004/jnccn.2010.0043 · 2010 · External reference
Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations
10.1002/14651858.cd012464.pub2 · 2018 · External reference
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
10.1200/jco.2007.13.9626 · 2008 · External reference
Bilateral oophorectomy and all-cause mortality in women with BRCA1 and BRCA2 sequence variations
10.1001/jamaoncol.2023.6937 · 2024 · External reference
Setting the threshold for surgical prevention in women at increased risk of ovarian cancer
10.1097/igc.0000000000001147 · 2018 · External reference
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers
10.1093/jnci/djn442 · 2009 · External reference
Selection of germline genetic testing panels in patients with cancer: ASCO guideline
10.1200/jco.24.00662 · 2024 · External reference
Epithelial ovarian cancer risk: a review of the current genetic landscape
10.1111/cge.13566 · 2020 · External reference
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
10.1038/s41431-021-00987-7 · 2022 · External reference
Genome-wide association studies for detecting cancer susceptibility
10.1093/bmb/ldq038 · 2011 · External reference
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
10.1038/ng.3826 · 2017 · External reference
Tutorial: a guide to performing polygenic risk score analyses
10.1038/s41596-020-0353-1 · 2020 · External reference
Developing and evaluating polygenic risk prediction models for stratified disease prevention
10.1038/nrg.2016.27 · 2016 · External reference
Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study
10.1136/jmedgenet-2018-105313 · 2018 · External reference
Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers
10.1093/jncics/pkaa021 · 2020 · External reference
2024 23/10/2025. Ovarian cancer audit feasibility pilot (OCAFP) - disease profile in england incidence
External reference
Systematic localization of common disease-associated variation in regulatory DNA
10.1126/science.1222794 · 2012 · External reference
From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus
10.1038/nature09266 · 2010 · External reference
From GWAS to function: using functional genomics to identify the mechanisms underlying complex diseases
10.3389/fgene.2020.00424 · 2020 · External reference
Oncogene-mediated alterations in chromatin conformation
10.1073/pnas.1112570109 · 2012 · External reference
The fundamental role of epigenetic events in cancer
10.1038/nrg816 · 2002 · External reference
Correlation of anti-tumour drug resistance with epigenetic regulation
10.1038/s41416-020-01183-y · 2021 · External reference
Functional interrogation of enhancer connectome prioritizes candidate target genes at ovarian cancer susceptibility loci
10.3389/fgene.2021.646179 · 2021 · External reference
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer
10.1158/1078-0432.ccr-14-2497 · 2015 · External reference
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
10.1186/s13048-023-01129-x · 2023 · External reference
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
10.1016/j.annonc.2023.05.005 · 2023 · External reference
A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score
10.3389/fgene.2023.1240068 · 2023 · External reference
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group
10.1200/jco.2011.39.8545 · 2012 · External reference
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer
10.1002/ijc.23017 · 2008 · External reference
When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer
10.1016/j.ygyno.2020.07.029 · 2020 · External reference
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
10.1038/ng.2564 · 2013 · External reference
The OncoArray consortium: a network for understanding the genetic architecture of common cancers
10.1158/1055-9965.epi-16-0106 · 2017 · External reference
TRACEBACK: testing of historical tubo-ovarian cancer patients for hereditary risk genes as a cancer prevention strategy in family members
10.1200/jco.21.02108 · 2022 · External reference
Biomarker-based ovarian carcinoma typing: a histological investigation in the Ovarian Tumor Tissue Analysis consortium
10.1158/1055-9965.epi-13-0391 · 2013 · External reference
An immunohistochemical algorithm for ovarian carcinoma typing
10.1097/pgp.0000000000000274 · 2016 · External reference
Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types
10.1158/2159-8290.cd-15-1227 · 2016 · External reference
Bam-readcount - rapid generation of basepair-resolution sequence metrics
10.21105/joss.03722 · 2022 · External reference
Prediction of breast cancer risk based on profiling with common genetic variants
10.1093/jnci/djv036 · 2015 · External reference
dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation
10.1101/gr.9.8.677 · 1999 · External reference
Unresolved reference
2001 · External reference
Proportionally difficult: testing for nonproportional hazards in Cox models
10.1093/pan/mpp044 · 2010 · External reference
Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model
10.1002/sim.9259 · 2022 · External reference
Proportional hazards tests and diagnostics based on weighted residuals
10.1093/biomet/81.3.515 · 1994 · External reference
10.1007/978-3-319-19425-7
10.1007/978-3-319-19425-7 · 2015 · External reference
Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
10.1016/j.ygyno.2011.01.020 · 2011 · External reference
Inherited mutations in women with ovarian carcinoma
10.1001/jamaoncol.2015.5495 · 2016 · External reference
A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects
10.1136/jmedgenet-2015-103077 · 2015 · External reference
The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2
10.1136/jmg-2022-108741 · 2023 · External reference
Panel testing for familial breast cancer: calibrating the tension between research and clinical care
10.1200/jco.2015.63.7454 · 2016 · External reference
Using polygenic risk modification to improve breast cancer prevention: study protocol for the PRiMo multicentre randomised controlled trial
10.1136/bmjopen-2024-087874 · 2024 · External reference
Personalised risk prediction in hereditary breast and ovarian cancer: a protocol for a multi-centre randomised controlled trial
10.3390/cancers14112716 · 2022 · External reference
